Medpace (MEDP) closed at $530.19 in the latest trading session, marking a -1.49% move from the prior day.
MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.
MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.
| Professional Services Industry | Industrials Sector | August James Troendle CEO | XETRA Exchange | US58506Q1094 ISIN |
| US Country | 5,900 Employees | - Last Dividend | - Last Split | 11 Aug 2016 IPO Date |
Medpace Holdings, Inc., founded in 1992 and headquartered in Cincinnati, Ohio, is a key player in the provision of comprehensive clinical research services for the development of drugs and medical devices. Spanning its operations across North America, Europe, and Asia, the company supports pharmaceutical, biotechnology, and medical device industries through the entire clinical development process, from Phase I to Phase IV, across a wide range of therapeutic areas. Its aim is to facilitate the journey of bringing new and innovative treatments to market efficiently and effectively.